Balance Sheet

Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding

Aptevo Therapeutics (APVO) Shares Issued (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Shares Issued for 9 consecutive years, with -$5.2 million as the latest value for Q4 2025.

Quarterly Shares Issued fell 24.63% to -$5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.2 million through Dec 2025, down 186.16% year-over-year, with the annual reading at $557000.0 for FY2025, 89.99% down from the prior year.
Shares Issued hit -$5.2 million in Q4 2025 for Aptevo Therapeutics, down from -$4.2 million in the prior quarter.
In the past five years, Shares Issued ranged from a high of $6.6 million in Q4 2022 to a low of -$5.2 million in Q4 2025.
Historically, Shares Issued has averaged $654666.7 across 5 years, with a median of $503000.0 in 2021.
Biggest five-year swings in Shares Issued: surged 43660.0% in 2022 and later plummeted 390.74% in 2024.
Year by year, Shares Issued stood at $15000.0 in 2021, then soared by 43660.0% to $6.6 million in 2022, then tumbled by 77.96% to $1.4 million in 2023, then tumbled by 390.74% to -$4.2 million in 2024, then decreased by 24.63% to -$5.2 million in 2025.
Business Quant data shows Shares Issued for APVO at -$5.2 million in Q4 2025, -$4.2 million in Q4 2024, and $5.8 million in Q3 2024.